| XBRANE Stock | | | SEK 0.19 0.01 5.00% |
COO
Mr. Siavash Bashiri was Chief Operating Officer and Head of Biosimilars of Xbrane Biopharma AB since 2015. Previously, he was CEO at the Company. He holds a MS in Molecular Biotechnology from Uppsala University. He has in recent years successfully led Xbrane Swedish operations and worked with several major pharmaceutical companies in the supply of customized protein production systems. Siavash Bashiri has also previous experience from Agilent Technologies where he was Head of Sales in EMEA for Agilent Technologies products. He also has experience of the process of commercialization of biotech startups. since 2015.
| Age | 40 |
| Tenure | 9 years |
| Phone | 46 7 60 34 67 33 |
| Web | https://www.xbrane.com |
Xbrane Biopharma Management Efficiency
The company has return on total asset
(ROA) of
(0.1313) % which means that it has lost $0.1313 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.3703) %, meaning that it generated substantial loss on money invested by shareholders. Xbrane Biopharma's management efficiency ratios could be used to measure how well Xbrane Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.
Xbrane Biopharma AB has accumulated 36.48
M in total debt with debt to equity ratio
(D/E) of 48.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Xbrane Biopharma has a current ratio of 1.42, which is within standard range for the sector. Debt can assist Xbrane Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Xbrane Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Xbrane Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Xbrane to invest in growth at high rates of return. When we think about Xbrane Biopharma's use of debt, we should always consider it together with cash and equity.
Xbrane Biopharma AB , a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. Xbrane Biopharma AB was founded in 2008 and is headquartered in Solna, Sweden. Xbrane Biopharma operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 35 people. Xbrane Biopharma AB (XBRANE) is traded on Stockholm Exchange in Sweden and employs 74 people.
Management Performance
Xbrane Biopharma Leadership Team
Elected by the shareholders, the Xbrane Biopharma's board of directors comprises two types of representatives: Xbrane Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xbrane. The board's role is to monitor Xbrane Biopharma's management team and ensure that shareholders' interests are well served. Xbrane Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xbrane Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nina Ivers, Head HR | |
| Maria Edebrink, Head Assurance | |
| Siavash Bashiri, COO, Head of Biosimilars | |
| Dina Jurman, Head of Clinical Affairs | |
| Anette Lindqvist, CFO Relations | |
| Martin mark, Chief Officer | |
| David Vikstrm, Chief Officer | |
| Associate Gier, CoFounder | |
| Samuel Wagner, CoFounder Board | |
| Erik Domines, G Counsel | |
Xbrane Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xbrane Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Other Information on Investing in Xbrane Stock
Xbrane Biopharma financial ratios help investors to determine whether Xbrane Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xbrane with respect to the benefits of owning Xbrane Biopharma security.